Parkinson's Clinical Trial Companion Accelerating Clinical Trials | Page 47

SPECIAL THANKS We are grateful to the following individuals for their leadership and innovation and for serving as case study examples of best practice in Parkinson’s disease research: + + Tanya Simuni, MD, of Northwestern University Feinberg school of Medicine – “Case Study #1: Engaging Key Stakeholders by Forming a Study Working Group” and “Case Study #4: STEADY-PD III” + + Samuel Frank, MD and David K. Simon, MD, PhD, of Beth Israel Deaconess Medical Center – “Case Study #2: Breaking Down Transportation Barriers to Research Participation” + + Irene Litvan, MD, of the University of California San Diego – “Case Study #5: An Educational Toolkit for Engaging the Hispanic Parkinson’s Community” + + David S. Russell, MD, PhD, of The Institute for Neurodegenerative Disorders (IND) – “Case Study #6: Institute for Neurodegenerative Disorders Physician Referral Network” + + Roseanne D. Dobkin, PhD, of Robert Wood Johnson Medical School – “Case Study #7: Using Facebook Ads to Recruit Study Participants” Special thanks to the following individuals for their thoughtful review of the manual and their insights on ways to improve clinical trial design, planning and implementation: + + Brittany L. Greco, CCRA, of the Center for Human Experimental Therapeutics, University of Rochester + + Michael A. Schwarzschild, MD, PhD, of Harvard Medical School and MassGeneral Institute for Neurodegenerative Disease + + Tanya Simuni, MD, of Northwestern University Feinberg School of Medicine Credits 45